Related Experiment Videos
Reduced levels of transforming growth factor-beta type I receptor in human gastric carcinomas
1First Department of Pathology, Hiroshima University School of Medicine.
Abstract:
The expressions of transforming growth factor beta (TGF-beta) and its receptor and TGF-beta inhibitory element (TIE)-binding protein were examined on human gastric carcinomas by Northern blot hybridization, immunohistochemistry, affinity labeling and gel retardation analysis. TGF-beta mRNA was expressed in tumor and normal tissues at various levels. Immunohistochemically, TGF-beta expression was confirmed to be present within tumor cells. Out of the 17 human gastric carcinoma tissues, 14 (82%) showed a reduction in the level of type I receptor (65 kDa) for TGF-beta when compared to corresponding normal mucosas. Interestingly, in seven of the 14 tumors the level of TIE-binding protein in the tumor tissue was lower than that in normal mucosa. Human gastric carcinoma cell line TMK-1, whose growth was inhibited by TGF-beta, had only type I receptor for TGF-beta and showed a high level of TIE-binding protein. Conversely, MKN-1, a TGF-beta-resistant cell line, exhibited an extremely low level of TGF-beta receptor and had no TIE-binding protein. These results overall indicate that although human gastric carcinoma cells produced TGF-beta, they showed a reduction in TGF-beta type I receptor and a low level of TIE-binding protein, resulting in escape from growth inhibition by TGF-beta.
Insights
Human gastric carcinomas produce transforming growth factor beta (TGF-beta) but escape its growth inhibition due to reduced TGF-beta type I receptor and low TIE-binding protein levels.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Transforming growth factor beta (TGF-beta) plays a crucial role in regulating cell growth and differentiation.
- Dysregulation of TGF-beta signaling is implicated in various cancers, including gastric carcinoma.
- Understanding the molecular mechanisms behind TGF-beta resistance in gastric cancer is vital for developing effective therapies.
Purpose of the Study:
- To investigate the expression levels of TGF-beta, its type I receptor, and TGF-beta inhibitory element (TIE)-binding protein in human gastric carcinomas.
- To determine the correlation between these factors and the sensitivity of gastric cancer cells to TGF-beta-mediated growth inhibition.
Main Methods:
- Northern blot hybridization to assess mRNA levels.
- Immunohistochemistry to localize protein expression within tumor cells.
- Affinity labeling and gel retardation analysis to evaluate receptor binding and protein interactions.
Main Results:
- TGF-beta mRNA was detected in both tumor and normal gastric tissues.
- A significant reduction (82%) in TGF-beta type I receptor levels was observed in gastric carcinomas compared to normal tissues.
- Lower levels of TIE-binding protein were found in a subset of tumors, correlating with TGF-beta resistance.
Conclusions:
- Human gastric carcinoma cells produce TGF-beta but exhibit reduced sensitivity to its growth-inhibitory effects.
- Downregulation of the TGF-beta type I receptor and TIE-binding protein contributes to TGF-beta resistance in gastric cancer.
- These molecular alterations may represent a mechanism by which gastric tumors evade TGF-beta-mediated growth suppression.